Measure opens the market for more than a dozen pharmaceutical companies to produce competing medicines
A Ozempic patent in Brazil will close this Friday (20), opening the market for more than a dozen pharmaceutical companies produce competitors for the medicine that has been used to control diabetes and lose weight. There is also an expectation for a price reduction in the marketwhich should reach 20% of the value in pharmacies.
According to Danish Novo Nordisk, manufacturer of Ozempico Closing a patent is a natural stage in the life cycle of any innovation. “The company is prepared to act solidly in this new context.”
In a statement, the company also said that innovation has been one of its central pillars for more than a century, and that it continues to guide its long-term strategy, translated into a portfolio of transformative medicines and a robust pipeline, with potential to generate new relevant advances in the care of chronic diseases serious illnesses and contribute to stronger, resilient and sustainable health systems.
The company also said that the Brazil continues to be one of the most strategic markets for Novo Nordisk globally, and that its plan remains unchanged.
Among the companies that have already requested registration with the National Health Surveillance Agency (Anvisa) to produce their own GLP-1-based medicines are EMS, Hypera, Biomm, Eurofarma, Cimed and Eli Lilly.
*Estadão Content
